Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
20 Dicembre 2023 - 1:59PM
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, today announced
its partnership with Enamine, a world-renowned provider of novel
molecules and contract research services, to generate enriched
screening libraries with insights from Recursion’s protein-ligand
interaction predictions spanning across Enamine’s massive library
of 36 billion compounds.
Chris Gibson, CEO and Co-founder of Recursion, traveled to Kyiv
to sign this partnership deal with Andrey Tolmachov, CEO and
Founder of Enamine. “I’m thrilled to announce this partnership as
we continue to advance insights in chemical space using the power
of relatable datasets and computational tools,” said Chris Gibson.
“We believe combining one of the largest chemical libraries with
our protein-ligand predictor tool, MatchMaker, will unlock the
ability to generate more powerful compound libraries for drug
discovery purposes.”
“Chemical space is limitless,” said Andrey Tolmachov. “While we
have developed a reliable approach to synthetically accessible
regions of chemical space, Recursion’s prediction technology has
further highlighted the drug discovery-useful subregions with the
molecules we can deliver.”
To begin the partnership, Enamine and Recursion will mutually
agree upon up to 100 biological targets around which they will
build screening libraries. From there, Recursion will utilize
MatchMaker’s predicted protein-ligand interactions for Enamine REAL
Space containing 36B compounds to design compound libraries
enriched for molecules that are likely to bind to biological
targets. Enamine may offer the resulting libraries to
customers for purchase and will co-brand any libraries under both
the Enamine and MatchMaker trademarks.
Recursion believes that these new libraries will be of interest
to customers given the additional predictive insights via
MatchMaker. The tool employs machine learning to evaluate the
suitability of small molecules for specific protein binding pockets
and is more scalable than traditional docking and physics-based
interaction simulations. Similar to Recursion's Phenomics platform,
MatchMaker's scalability affords a comprehensive view of
biochemistry; it can predict binding activity for large quantities
of molecules across the proteome. The predicted data can guide the
selection of wet-lab experiments, helping to expedite progress
across a diverse range of targets and chemical areas, and can act
as a preliminary screening tool for more computationally intensive
precision modeling techniques.
As part of the agreement, Recursion will receive a significant
number of unique REAL compounds of Recursion’s choosing to augment
its internal compound library, at no cost. Furthermore,
Recursion will receive preferential pricing on any enriched
screening libraries made available to Enamine customers as part of
the collaboration.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company
leading the space by decoding biology to industrialize drug
discovery. Enabling its mission is the Recursion OS, a platform
built across diverse technologies that continuously expands one of
the world’s largest proprietary biological and chemical datasets.
Recursion leverages sophisticated machine-learning algorithms to
distill from its dataset a collection of trillions of searchable
relationships across biology and chemistry unconstrained by human
bias. By commanding massive experimental scale — up to millions of
wet lab experiments weekly — and massive computational scale —
owning and operating one of the most powerful supercomputers in the
world, Recursion is uniting technology, biology, and chemistry to
advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montréal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on Twitter and LinkedIn.
About Enamine
Headquartered in Kyiv, Ukraine, Enamine is a scientifically
driven integrated discovery Contract Research Organization with
unique partnering opportunities in exploring new chemical space.
The company combines access to the in-house produced screening
compounds (4M in stock) and building blocks (300K in stock) with a
comprehensive platform of integrated discovery services to advance
and accelerate the efforts in Drug Discovery. Enamine has developed
the largest offering of make-on-demand compounds that includes
trillions of Enamine REAL molecules and over a billion of Enamine
MADE building blocks. The company’s unique knowledge-based approach
allows for fast and inexpensive delivery of novel entities from the
above make-on-demand chemical space.
Forward-Looking Statements
This document contains information that includes or is based
upon "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995, including, without
limitation, those regarding the outcomes and benefits expected from
the Enamine partnership, including the potential to generate new
compound libraries and accelerate cycles for advancing chemical
series; the Recursion OS and other technologies, including
MatchMaker and the Enamine REAL Space chemical library; and all
other statements that are not historical facts. Forward-looking
statements may or may not include identifying words such as "plan,"
"will," "expect," "anticipate," "intend," "believe," "potential,"
"continue," and similar terms. These statements are subject to
known or unknown risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements, including but not limited to: challenges inherent
in pharmaceutical research and development, including the timing
and results of preclinical and clinical programs, where the risk of
failure is high and failure can occur at any stage prior to or
after regulatory approval due to lack of sufficient efficacy,
safety considerations, or other factors; our ability to leverage
and enhance our drug discovery platform; our ability to obtain
financing for development activities and other corporate purposes;
the success of our collaboration activities; our ability to obtain
regulatory approval of, and ultimately commercialize, drug
candidates; our ability to obtain, maintain, and enforce
intellectual property protections; cyberattacks or other
disruptions to our technology systems; our ability to attract,
motivate, and retain key employees and manage our growth; and other
risks and uncertainties such as those described under the heading
"Risk Factors" in our filings with the U.S. Securities and Exchange
Commission, including our most recent Quarterly Report on Form 10-Q
and our Annual Report on Form 10-K. All forward-looking statements
are based on management's current estimates, projections, and
assumptions, and Recursion undertakes no obligation to correct or
update any such statements, whether as a result of new information,
future developments, or otherwise, except to the extent required by
applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Grafico Azioni Recursion Pharmaceuticals (NASDAQ:RXRX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Recursion Pharmaceuticals (NASDAQ:RXRX)
Storico
Da Set 2023 a Set 2024